Literature DB >> 15009631

Cyclin-dependent kinase-5 in neurodegeneration.

Shirley B Shelton1, Gail V W Johnson.   

Abstract

Cyclin-dependent kinase-5 (CDK5) is predominantly active in the nervous system and it is well established that CDK5 is essential in neuronal development. In addition to its recognized role in development, there is increasing evidence that CDK5 may be involved in the pathogenesis of several neurodegenerative disorders. Although studies have shown that CDK5 can modulate cell death and survival, controversy still exists as to the exact role CDK5 may play in neurodegenerative processes. This review will highlight recent data on the possible roles of CDK5 in neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009631     DOI: 10.1111/j.1471-4159.2003.02328.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  51 in total

1.  Inhibition of the cdk5/MEF2 pathway is involved in the antiapoptotic properties of calpain inhibitors in cerebellar neurons.

Authors:  Ester Verdaguer; Daniel Alvira; Andrés Jiménez; Victor Rimbau; Antoni Camins; Mercè Pallàs
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

Review 2.  Cell cycle molecules define a pathway required for neuron death in development and disease.

Authors:  Lloyd A Greene; David X Liu; Carol M Troy; Subhas C Biswas
Journal:  Biochim Biophys Acta       Date:  2006-12-13

3.  Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3beta.

Authors:  Farah H Bardai; Santosh R D'Mello
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

4.  Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies.

Authors:  Joao P Lopes; Catarina R Oliveira; Paula Agostinho
Journal:  Cell Mol Neurobiol       Date:  2007-10-27       Impact factor: 5.046

Review 5.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

Review 6.  Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders.

Authors:  Jerel Adam Fields; Wilmar Dumaop; Leslie Crews; Anthony Adame; Brian Spencer; Jeff Metcalf; Johnny He; Edward Rockenstein; Eliezer Masliah
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

7.  The Notch signaling inhibitor DAPT down-regulates cdk5 activity and modulates the distribution of neuronal cytoskeletal proteins.

Authors:  Jyotshnabala Kanungo; Ya-Li Zheng; Niranjana D Amin; Harish C Pant
Journal:  J Neurochem       Date:  2008-07-04       Impact factor: 5.372

Review 8.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

9.  Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model.

Authors:  Yun Ding; Aimin Qiao; Ziqing Wang; J Shawn Goodwin; Eun-Sook Lee; Michelle L Block; Matthew Allsbrook; Michael P McDonald; Guo-Huang Fan
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

10.  Functional characterization of CDK5 and CDK5R1 mutations identified in patients with non-syndromic intellectual disability.

Authors:  Silvia Moncini; Paola Castronovo; Alessandra Murgia; Silvia Russo; Maria Francesca Bedeschi; Marta Lunghi; Angelo Selicorni; Maria Teresa Bonati; Paola Riva; Marco Venturin
Journal:  J Hum Genet       Date:  2015-12-10       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.